https://pro.thestreet.com/thefly-newsbreaks/halo-piper-sandler-gets-more-bearish-on-halozyme-downgrades-shares
Piper Sandler gets more bearish on Halozyme, downgrades shares | TheStreet Pro
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's...
piper sandlergetshalozymedowngradesshares
https://sa.m.netdania.com/news/Convergence%20Investment%20Partners%20LLC%20Grows%20Stock%20Holdings%20in%20Halozyme%20Therapeutics,%20Inc.%20(NASDAQ:HALO)/Buzz%20FX/%7Bna:%5B%7Bt:%5B%22BUZZ_FX_GF%22%5D%7D%5D,hf:0%7D/tcnews/a1f5aea77f8bfcb720116161687fda491d128fe8@%7B%22Syms%22:%5B%5D,%22Inf%22:%7B%22PBL%22:%22MarketBeat%22%7D%7D/1739964371
Convergence Investment Partners LLC Grows Stock Holdings in Halozyme Therapeutics, Inc....
Convergence Investment Partners LLC Grows Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - NetDania News
investment partnershalozyme therapeuticsconvergencellcgrows
https://www.finanznachrichten.de/aktien-analysen/halozyme-therapeutics-inc.htm
HALOZYME THERAPEUTICS-AKTIE kaufen? Analysen, Kursziele & Empfehlungen zu A0DLHS
HALOZYME THERAPEUTICS-Aktie jetzt kaufen? Analysen und Kursziele:
halozyme therapeuticsaktiekaufenanalysenempfehlungen
https://www.sahmcapital.com/news/content/halozyme-vertex-hypercon-deal-opens-new-royalty-and-growth-pathways-2026-04-10
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways
Halozyme Therapeutics (NasdaqGS:HALO) announced a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon technology....
growth pathwayshalozymevertexdealopens
https://pitchgrade.com/companies/halozyme-therapeutics-inc
Halozyme Therapeutics: Business Model, SWOT Analysis, and Competitors 2026 - PitchGrade
Comprehensive 2026 analysis of Halozyme Therapeutics: business model, SWOT analysis, competitors, and real financial data ($1.40B revenue, $7.95B market cap)...
halozyme therapeuticsbusiness modelswot analysiscompetitors
https://ipverse.greyb.com/ptab-web/cases/case-details/PGR2025-00046
Merck Sharp & Dohme LLC v. Halozyme, Inc. et al. - PGR2025-00046 - IP Verse
merck sharpet alllcvhalozyme
https://catalystalert.io/news/ada6b4f2-1237-4d64-a321-100129584819
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road | CatalystAlert
May 6, 2026 - Opinion piece analyzing Halozyme Therapeutics' business model as a drug-delivery platform generating royalty income. No material company announcements, clinical
halozyme therapeuticsdrug deliverytoll roadroyaltyengine
https://www.home.saxo/de-ch/markets/stocks/halo-xnas
Halozyme Therapeutics Inc. aktie | Saxo Bank Schweiz
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies.
halozyme therapeuticssaxo bankincaktieschweiz